Top Markets
Coin of the day
Rafael Holdings, Inc. Rafael Holdings, Inc.

Rafael Holdings, Inc.

RFL
Rang in aandelen #21321
Rafael Holdings, Inc. holds strategic investments in both early-stage and... Rafael Holdings, Inc. holds strategic investments in both early-stage and clinical pharmaceutical companies, alongside a portfolio of commercial real estate assets situated in the United States and Israel. The company's business activities are structured into two primary divisions: Pharmaceuticals and Real Estate. Its Real Estate segment manages and leases a commercial office complex, which features an integrated 800-space public parking facility. The Pharmaceutical division, conversely, focuses on developing and bringing to market therapies designed to capitalize on the metabolic distinctions between healthy cells and malignant ones. The firm's flagship drug candidate is CPI-613 (devimistat), currently undergoing evaluation in numerous clinical trials, including two pivotal Phase III registrational studies for the treatment of advanced pancreatic cancer and relapsed/refractory acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Aandeelprijs
$2.15
Laatst gesynchroniseerd: 2026-08-21
Marktkapitalisatie
$110.06M
Verandering (1 dag)
13.46%
Verandering (1 jaar)
37.76%
Land
US
Handel Rafael Holdings, Inc. (RFL)

Categorie

P/B-ratio voor Rafael Holdings, Inc. (RFL)
P/B-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van Rafael Holdings, Inc. is de huidige P/B-ratio (TTM) 0. Eind 2026 had het bedrijf een P/B-ratio van 0.
P/B-ratiohistoriek voor Rafael Holdings, Inc. van 2026 tot 2026
P/B-ratio aan het einde van elk jaar
Jaar P/B-ratio Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
P/B-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/B-ratio Verschil in P/B-ratio Land
5.3572 -
US
- -
DE
1.9218 -
CN
- -
DE
2.3388 -
US